Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUC-MSC-sEV-001 in Neurodegenerative Diseases
NCT06607900Phase 1Not yet recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Jul 2025
- Primary completion
- Aug 2027
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of exosomes derived from human umbilical cord blood mesenchymal stem cells in Alzheimer's disease (AD), Parkinson's disease (PD), multiple system atrophy (MSA) and 3 more, sponsored by Xuanwu Hospital. Primary endpoints: Alzheimer's Disease Assessment Scale-Cognitive Subscale at 12 months, MDS-Unified Parkinson's Disease Rating Scale at 12 months and 4 more. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
exosomes derived from human umbilical cord blood mesenchymal stem cells
03
Conditions
Alzheimer's disease (AD)Parkinson's disease (PD)multiple system atrophy (MSA)dementia with Lewy bodies (DLB)frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NCT06607900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06607900.